Source comparison
CJC-1295 No DAC & Ipamorelin Dose Response Research: Protocol Comparison
Monotherapy (CJC-1295 only) 100mcg 0mcg 1× daily (bedtime) 4.2 ± 1.1 18–22% Suboptimal. Somatostatin feedback limits GH release. Suitable only when ipamorelin unavailable. Standard Synergistic Protocol 2× daily (morning, bedtime) 12.8 ± 2.4 55–68% Gold standar
This comparison does not assign a generated winner or score.
- Monotherapy (CJC-1295 only)
- 100mcg
- 0mcg
- 1× daily (bedtime)
- 4.2 ± 1.1
- 18–22%
- Suboptimal. Somatostatin feedback limits GH release. Suitable only when ipamorelin unavailable.
- Standard Synergistic Protocol
- 2× daily (morning, bedtime)
- 12.8 ± 2.4
- 55–68%
- Gold standard for research. Maximizes GH pulse amplitude without receptor desensitization. Aligns with published dose-response data.
- High-Dose Synergistic Protocol
- 200mcg
- 14.1 ± 3.0
- 62–75%
- Marginal IGF-1 benefit over standard protocol but higher cortisol/prolactin elevation risk. Reserved for models requiring maximal anabolic signaling.
- Pulse-Mimetic Protocol
- 3× daily (morning, afternoon, bedtime)
- 10.6 ± 2.2 (per pulse)
- 70–82%
- Replicates physiological pulsatility most closely. Labor-intensive but produces highest sustained IGF-1 without tachyphylaxis across 8–12 week protocols.
- Overdose (Desensitization Risk)
- 300mcg+
- 2× daily
- 9.3 ± 3.8 (declining after week 2)
- 48–55% (declining)
- Causes GHS-R1a receptor downregulation by week 3. Not recommended. Diminishing returns outweigh any short-term GH elevation.